Novel Precision Gene Therapy for Friedreich’s Ataxia with Dr. Gabriel Brooks Solid Biosciences TRANSCRIPT
Release Date: 04/23/2026
Empowered Patient Podcast
Zach Shultz, Senior Director of Product Policy and Solutions at EnableComp, describes the challenges of revenue cycle management in healthcare with a focus on the strategic importance of full-time equivalent (FTE) allocation. Hospitals could improve their bottom line by outsourcing complex, low-reimbursement claims, such as those from the VA so that in-house staff can focus on higher-value commercial claims. Despite the emergence of AI as a significant factor in automating the review process, human intervention is irreplaceable for quality assurance, managing escalations, and resolving...
info_outlineEmpowered Patient Podcast
Zach Shultz, Senior Director of Product Policy and Solutions at EnableComp, describes the challenges of revenue cycle management in healthcare with a focus on the strategic importance of full-time equivalent (FTE) allocation. Hospitals could improve their bottom line by outsourcing complex, low-reimbursement claims, such as those from the VA so that in-house staff can focus on higher-value commercial claims. Despite the emergence of AI as a significant factor in automating the review process, human intervention is irreplaceable for quality assurance, managing escalations, and resolving...
info_outlineEmpowered Patient Podcast
Lon Hecht, CEO of Care2U, has designed an innovative model of providing in-home high-acuity care as an alternative to emergency room visits or hospitalizations. The process includes sending a clinician to the home within 2-4 hours, with extensive mobile medical equipment, and physician support via telehealth. Benefits include better patient recovery outcomes, significant cost savings for patients and payers, and prevention of costly hospital readmissions. Lon explains, "My company, Care2U, and I are bringing high acuity care into the home. So think of it as kind of a...
info_outlineEmpowered Patient Podcast
Lon Hecht, CEO of Care2U, has designed an innovative model of providing in-home high-acuity care as an alternative to emergency room visits or hospitalizations. The process includes sending a clinician to the home within 2-4 hours, with extensive mobile medical equipment, and physician support via telehealth. Benefits include better patient recovery outcomes, significant cost savings for patients and payers, and prevention of costly hospital readmissions. Lon explains, "My company, Care2U, and I are bringing high acuity care into the home. So think of it as kind of a...
info_outlineEmpowered Patient Podcast
Patty Hayward, General Manager of healthcare and life sciences at Talkdesk, describes how a hybrid model of humans and AI is reshaping healthcare contact centers. Patient access and revenue cycle management are the primary, interconnected challenges for these centers, and modern large-language AI is being used to handle complex scheduling logic. Data analytics helps identify patterns in patient inquiries, predict demand peaks, and move care from reactive to proactive. The expectation is that AI agents will guide patients, becoming a normal and accepted part of healthcare. Patty explains, "I...
info_outlineEmpowered Patient Podcast
Patty Hayward, General Manager of healthcare and life sciences at Talkdesk, describes how a hybrid model of humans and AI is reshaping healthcare contact centers. Patient access and revenue cycle management are the primary, interconnected challenges for these centers, and modern large-language AI is being used to handle complex scheduling logic. Data analytics helps identify patterns in patient inquiries, predict demand peaks, and move care from reactive to proactive. The expectation is that AI agents will guide patients, becoming a normal and accepted part of healthcare. Patty explains, "I...
info_outlineEmpowered Patient Podcast
Scott Xiao, Co-Founder and CEO of Luminopia, is developing a novel, FDA -cleared VR-based treatment for neurovisual disorders with a primary focus on amblyopia, lazy eye, in children aged 4- 12 years old. This approach uses popular TV shows to create an engaging, effective therapy that trains the eyes to work together and is designed as a replacement for traditional eye patching. Clinical data indicate that the vision improvements from this therapy are durable and that the VR approach is well-received by children and their parents. Scott explains, "We are pioneering a new class of...
info_outlineEmpowered Patient Podcast
Scott Xiao, Co-Founder and CEO of Luminopia, is developing a novel, FDA -cleared VR-based treatment for neurovisual disorders with a primary focus on amblyopia, lazy eye, in children aged 4- 12 years old. This approach uses popular TV shows to create an engaging, effective therapy that trains the eyes to work together and is designed as a replacement for traditional eye patching. Clinical data indicate that the vision improvements from this therapy are durable and that the VR approach is well-received by children and their parents. Scott explains, "We are pioneering a new class of...
info_outlineEmpowered Patient Podcast
Joseph Kleiman, President of Buzz Health, is working to improve price transparency and affordability of prescription drugs. He states that providing price transparency as early as possible in the prescription process is critical for prescribers, patients, and health plans to make better, more cost-effective decisions. To achieve true transparency, all parties in the ecosystem must cooperate and share data, moving beyond pricing visibility to fully integrate systems and use real-time information to improve patient adherence and lower costs. Joseph explains, "Buzz Health really focuses on...
info_outlineEmpowered Patient Podcast
Joseph Kleiman, President of Buzz Health, is working to improve price transparency and affordability of prescription drugs. He states that providing price transparency as early as possible in the prescription process is critical for prescribers, patients, and health plans to make better, more cost-effective decisions. To achieve true transparency, all parties in the ecosystem must cooperate and share data, moving beyond pricing visibility to fully integrate systems and use real-time information to improve patient adherence and lower costs. Joseph explains, "Buzz Health really focuses on...
info_outlineDr. Gabriel Brooks is Chief Medical Officer at Solid Biosciences, a precision molecular genetic medicines company focused on rare cardiovascular and neuromuscular diseases, including Friedreich's ataxia. Currently, there are very limited treatments for this rare, progressive neurologic disease caused by a genetic deficiency. Solid Biosciences' novel gene therapy uses dual-route administration to deliver directly to the heart and brain and to replace the missing frataxin gene, which is critical for energy production.
Dr. Brooks explains, "Our flagship program is our DMD program, where we have two clinical trials, a first-in-human INSPIRE study, and a double-blind randomized placebo-controlled phase three trial for the SGT-003 DMD medicine. And for Friedreich’s ataxia, we have the SGT-212 program, which uses a novel dual route of administration to target not only the cardiomyopathy, but also uses direct injection into the dentate nucleus. We're trying to address the central pathophysiology of the ataxia that patients live with every day."
"So Friedrich's ataxia is a rare and devastating neurologic disease that afflicts around 5,000 patients in the United States and much more actually in Europe. There is a genetic predisposition. And Friedrich’s ataxia is really a disease where the patients experience difficulty in moving, what's called ataxia, which you could think of as poor coordination, where when they try to move, their brain is sending a signal to their muscles, let's say to grab that cup of coffee or climb the stairs."
"In fact, there are specific neurologic tests in terms of looking at nerve conduction and other things that can make the formal diagnosis. And certainly, we can get there with genetic testing. And what you're picking up on is absolutely something that's important with rare disease, is that oftentimes there's a lag between when a patient first manifests symptoms and when they ultimately have the diagnosis. In Friedrich's ataxia, like other genetic diseases, it is horrible. And so, for patients who do make the diagnosis of Friedreich's ataxia, there is often what we call cascade screening, where we look for the disease gene in relatives. Oftentimes, it's then that siblings are identified, and eventually they start manifesting the disease as well."
#SolidBiosciences #GeneTherapy #GeneTherapyResearch #RareDiseases #FriedreichsAtaxia #PrecisionMedicine #Neurology #Cardiology #ClinicalTrials #MedicalInnovation #HealthcareInnovation #SolidBiosciences
